Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

STATUS

Recruiting
End date

Mar 28, 2026
participants needed

224
sponsor

Global Blood Therapeutics

Send

Updated on 19 February 2024

See if I qualify

anemia

cerebral blood flow

gbt440

transcranial doppler ultrasonography

voxelotor

pediatric

Summary

This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged 2 to < 15 years old, with Sickle Cell Disease. The primary objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound) measurements in SCD participants in this age range.

Description

This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged 2 to < 15 years old, with Sickle Cell Disease. The study will be conducted at approximately 50 international clinical sites, and will enroll approximately 224 participants. Participants will be randomized in a 1:1 ratio to receive voxelotor or placebo. All participants younger than 12 years of age and randomized to voxelotor will receive a dose based on their body weight, to provide exposure corresponding to the adult dose of 1500 mg/day.

Details

Condition	SICKLE CELL ANEMIA
Age	2-14 years
Treatment	Placebos, Voxelotor
Clinical Study Identifier	NCT04218084
Sponsor	Global Blood Therapeutics
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Male or female participants with Sickle Cell Anemia (SCA)
	TCD time averaged maximum of the mean velocity (TAMMV) arterial cerebral blood flow 170 to < 200cm/sec during the Screening Period
	Hb 5.5 and 10.5 g/dL during screening
	For participants taking HU, the dose of HU (mg/kg) must be stable for at least 90 days prior to signing the informed consent form (ICF) and/or assent form, and with no anticipated need for dose adjustments (other than weight based) or for initiation of HU for non-chronic use during the study, in the opinion of the Investigator
	Written informed parental/guardian consent and participant assent (where applicable) has been obtained per IRB/EC policy and requirements, consistent with ICH guidelines
Exclusion Criteria
	Body weight < 5kg at the screening visit
	Hospitalization for VOC or acute chest syndrome (ACS) within the 14 days prior to execution of informed consent/assent (see Section [7.2.5.1](telnet://7.2.5.1) for the definition of VOC)
	More than 10 VOCs within the past 12 months that required hospitalization, emergency room, or clinic visit
	Stroke resulting in focal neurological deficit; previous silent infarcts are permitted
	Known history or findings, including screening magnetic resonance imaging (MRI)/magnetic imaging angiography (MRA) findings, suggestive of significant cerebral vasculopathy (eg, moyamoya or significant vasculopathy)
	History of seizure disorder (History of febrile seizures is permissible if there have been no seizures within the 12 months prior to randomization)
	Has been treated with erythropoietin or other hematopoietic growth factors within 28 days of signing informed consent/assent or if, in the opinion of the Investigator, there is an anticipated need for such agents during the study
	RBC transfusion therapy (also termed chronic, prophylactic, or preventative transfusion) or has received an RBC transfusion or exchange transfusion for any reason within 90 days of signing the informed consent/assent

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

anemia

cerebral blood flow

gbt440

transcranial doppler ultrasonography

voxelotor

pediatric

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease